Loading clinical trials...
Loading clinical trials...
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mitchell Cancer Institute
Mobile, Alabama, United States
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona, United States
Cancer Specialists, LLC
Jacksonville, Florida, United States
University of Maryland
Baltimore, Maryland, United States
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
Texas Oncology - Paris
Fort Worth, Texas, United States
US Oncology - Texas Oncology
Kyle, Texas, United States
Liverpool Hospital
Liverpool, Australia
Start Date
March 1, 2026
Primary Completion Date
May 1, 2030
Completion Date
December 1, 2032
Last Updated
February 10, 2026
150
ESTIMATED participants
Pirtobrutinib
DRUG
Idelalisib
DRUG
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT05006716
NCT07277231
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06859424